AstraZeneca's FluMist nasal spray vaccine approved for self-administration
The U.S. FDA has given the green light for AstraZeneca's FluMist nasal spray vaccine to be self-administered or administered ...
Daily1d
FDA approves Benralizumab for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...
Pharmaceutical Technology1d
Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseases
NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod
Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
pulmonologyadvisor1d
FDA Approves Fasenra for Eosinophilic Granulomatosis With Polyangiitis
The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
Yahoo Finance1d
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
AstraZeneca’s Fasenra (benralizumab) met its primary endpoint in the MANDARA trial by demonstrating non-inferiority to the ...
Pharmabiz2d
US FDA approves AstraZeneca’s Fasenra to treat eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
MARKET REPORT: St Tropez maker burnt by Nigerian currency woes
The stock fell 15% after the consumer goods firm swung to a loss of £96m for the 12 months to the end of May, against a £62m ...
Managed Healthcare Executive2d
FDA Approves Fasenra for Treatment of Eosinophilic Granulomatosis with Polyangiitis
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
Medscape2d
FDA Approves Benralizumab for EGPA Vasculitis Indication
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
ENDPOINTS NEWS2d
FDA ap­proves As­traZeneca’s asth­ma med­ica­tion Fasen­ra to treat rare au­toim­mune con­di­tion
A few months after a key label expansion, AstraZeneca’s asthma treatment Fasenra has received FDA approval to treat a rare ...
MedPage Today2d
FDA OKs New Option for Rare Immune-Mediated Vasculitis
EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...